BRAF and melanoma: Excitingly, whereas both PLX4032 and the FOXM1-S704 DRI peptide individually reduced EM5 melanoid viability, their combination decreased viability to levels below background, indicating that FOXM1-S704 can be additive to BRAF inhibition against human melanoma (Figure 7e).